<DOC>
	<DOCNO>NCT00852709</DOCNO>
	<brief_summary>This Phase I study design determine MTD ass toxicity associate clofarabine follow fractionated cyclophosphamide patient &gt; 1 year age &lt; 21 year age relapse refractory acute leukemia . There 25 35 patient enrol . Cohorts 3 6 patient receive escalated dos clofarabine follow fractionated cyclophosphamide MTD reach . There intra-patient dose escalation . Single-agent cyclophosphamide administer 2-hour IVI Day 0 cycle 1 . On Days 1 , 2 , 3 Days 8 , 9 , 10 clofarabine administer IVI 2 hour dose cyclophosphamide ( see treatment schema ) . A cycle define 28 day .</brief_summary>
	<brief_title>Phase I Dose-Escalation Trial Clofarabine Followed Escalating Doses Fractionated Cyclophosphamide Children With Relapsed Refractory Acute Leukemias</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 adolescent/young adult patient . Lansky Performance Index &gt; 50 pediatric patient le age 10 year . Laboratory value obtain &lt; 7 day prior receive study treatment : Total bilirubin &lt; 1.5 mg/dL unless elevate due hemolysis . The conjugated serum bilirubin prior study entry must within normal range . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; 2.5 Ã— upper limit normal ( ULN ) Serum creatinine &lt; 1.0 mg/dL adolescent/young adult ( patient 12 17 year age ) . For pediatric patient serum creatinine ULN , creatinine clearance &gt; 90 ml/min/1.73m2 calculate use Schwartz formula may enrol . Collected creatinine clearance may substitute . Patients 18 year old ( Adult population ) : Serum creatinine &lt; 1.0 mg/dL ; serum creatinine &gt; 1.0 mg/dL , estimate glomerular filtration rate ( GFR ) must &gt; 60 mL/min/1.73 m2 Cardiac function must normal per institution normal measure echocardiogram ( ECHO ) within 7 day . Patients evidence myositis detect abnormal serum creatine kinase and/or myoglobin . No chemotherapy , radiation , major surgery within 2 week prior first dose study drug except 5azacytidine , thalidomide , hydroxyurea , imatinib ( Gleevec ) , interferon must discontinue least 3 day study entry patient recover toxic side effect therapy . In instance progressive disease , antileukemia therapy may administer within 2week period long subject recover toxic effect therapy . Also , intrathecal therapy may administer within 2week period subject CNS disease . Patients allogeneic autologous hematopoietic stem cell transplant . Patients must discontinue growth factor , except Procrit ( epoetin ) , least 1 week study . Patients know HIV positive status AIDS . Patients know active Hepatitis B , Hepatitis C cirrhosis . History severe coronary artery disease , include myocardial infarction within previous 3 month , arrhythmias atrial flutter fibrillation require medication , uncontrolled congestive heart failure . Patients active uncontrolled infection , fever infection , evidence progressive disease CT scan lung , sinus , abdomen . Patients antimicrobial therapy stable , CT scan must stable 4 week , may enrol must evidence active infection . Patients fever due leukemia may enrol . Pregnant lactating patient . Female patient childbearing potential must negative serum pregnancy test within 14 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Myelodysplastic syndrome transform AML ( AML/MDS )</keyword>
	<keyword>Treatment-related AML</keyword>
	<keyword>AML evolve myeloproliferative disorder ( MPD )</keyword>
	<keyword>Acute lymphocytic leukemia ( ALL )</keyword>
	<keyword>Acute promyelocytic leukemia ( APL ) refractory arsenic therapy retinoic acid therapy</keyword>
	<keyword>Relapsed and/or refractory acute leukemia progressive disease since last therapy</keyword>
	<keyword>Chronic myelogenous leukemia ( CML ) accelerate phase blast crisis refractory imatinib</keyword>
	<keyword>High-risk MPD include myelofibrosis , chronic myelomonocytic leukemia ( CMML , relapse refractory juvenile myelomonocytic leukemia ( JMML ) .</keyword>
</DOC>